Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...

November 24, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for the oral formulation of aripiprazole (Abilify tablets, orally disintegrating tablets, and oral ...

TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...

TOKYO, JAPAN & PRINCETON, NEW JERSEY, FEBRUARY 29 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) ...

TOKYO and PRINCETON, N.J., Nov. 6 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY - News) announced today that the U.S. Food and Drug Administration (FDA) approved the ...

Aristada and Aristada Initio (aripiprazole lauroxil) are prescription drugs used to treat schizophrenia. The drug is given by a healthcare professional as an injection into a muscle every 4, 6, or 8 ...

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1 Windsor, United Kingdom/Valby, Denmark, 27 March 2024 – Otsuka Pharmaceutical ...

Abilify is available in several different brand-name versions: Abilify comes as a tablet that you swallow. Abilify MyCite comes as a tablet with a sensor that you swallow.* Abilify Maintena comes as ...

Open field and inhibitory avoidance tasks were used. Thirty min before performing the behavioral tasks, adult male CF-1 mice were administered aripiprazole (1, 3 or 10 mg/kg, ip) once for the acute ...

FARMINGTON, Conn., April 3 -- The atypical antipsychotic aripiprazole (Abilify), modified the behavioral and physiological effects of alcohol, according to a preliminary study. Aripiprazole ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched ...